Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIBOHCA phase II study of 2-iminobiotin after out-of-hospital cardiac arrest
NL-OMON47307Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 2-iminobiotin in hypoxic-ischemic encephalopathy (HIE) and post-cardiac arrest syndrome (PCAS) (3 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Short-term safety and tolerability and Pharmacokinetics of 2-iminobiotin. Started May 2016; status: active, not recruiting.
02
Drugs
2-iminobiotin
03
Conditions
hypoxic-ischemic encephalopathy (HIE)post-cardiac arrest syndrome (PCAS)
Beyond the preview
Go deeper on NL-OMON47307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47307.